
Trump's W.H.O. Exit Throws Smallpox Defenses Into Upheaval
President Trump's order that the United States exit the World Health Organization could undo programs meant to ensure the safety, security and study of a deadly virus that once took half a billion lives, experts warn. His retreat, they add, could end decades in which the agency directed the management of smallpox virus remnants in an American-held cache.
Health experts say discontinuation of the W.H.O.'s oversight threatens to damage precautions against the virus leaking into the world, and to disrupt research on countermeasures against the lethal disease. They add that it could also raise fears among allies and adversaries that the United States, under a veil of secrecy, might weaponize the smallpox virus.
'I've been in that lab,' said Thomas R. Frieden, a former director of the Centers for Disease Control and Prevention in Atlanta, where the American cache resides. 'Imagine a submarine inside a building and the people walking around in spacesuits. It looks like something out of a movie.' To reduce smallpox risks and misperceptions, Dr. Frieden added, 'we need to open ourselves up to inspection.'
On Monday, Daniel R. Lucey, a Dartmouth medical professor, posted an article on the blog of the Infectious Diseases Society of America warning that Mr. Trump's W.H.O. exit could imperil 'smallpox virus storage, experiments, reporting and inspections.'
A half century ago, the W.H.O. purged the smallpox virus from human populations after the scourge had killed people for thousands of years. Dr. Frieden called it 'one of the greatest accomplishments not just of medical science but global collaboration.'
While the germ was eradicated in people, two repositories were preserved to allow study of the virus should it re-emerge: one in Atlanta, the other in Russia. To curb leaks, both caches are stored in special labs classified as Biosafety Level 4, the highest tier of protection.
In recent years, the W.H.O., based in Geneva, has ruled on the safety and scientific merit of proposed studies of smallpox by both the C.D.C. and its Russian counterpart. It has the authority to grant or refuse permission despite its role being described publicly as advisory. The agency also regularly inspects the smallpox labs for safety lapses.
Health experts warn that Mr. Trump's exit from international oversight could end Washington's ability to scrutinize Moscow's smallpox cache. 'If we want to inspect the Russian lab,' Dr. Frieden said, 'we need to be part of W.H.O.'
Russia probably hides some smallpox virus for military use, according to a federal intelligence assessment. Health experts also warn that the American exit from the W.H.O. could prompt fears that the United States might weaponize the lethal virus.
In his first term as president, Mr. Trump lashed out at the W.H.O. over its handling of the coronavirus pandemic and, in July 2020, ordered a withdrawal. But six months later, before the separation could be completed, former President Joseph R. Biden Jr. reversed Mr. Trump's decision on his first day in office.
This time around, Mr. Trump came on stronger, issuing an executive order within hours of taking office that gave notice of the U.S. withdrawal. He also told his administration to identify U.S. and global partners that could 'assume necessary activities' that the W.H.O. had previously carried out.
A week later, the C.D.C. was ordered to end all collaboration with the W.H.O.
It is not clear if the W.H.O. and the C.D.C. have completely ended their smallpox cooperation. Their replies to email queries seemed contradictory, and the White House did not respond.
Christian Lindmeier, a W.H.O. spokesman, said officials at the agency were still seeking to clarify the implications of Mr. Trump's order. The agency, he added, 'is ready to work with the new U.S. Administration to sustain our vital collaboration.' The next smallpox inspection, Mr. Lindmeier added, is scheduled for May 2026.
The C.D.C. is part of the department of Health and Human Services, whose communications director, Andrew G. Nixon, said only that it was complying with Mr. Trump's order for the U.S. to withdraw from the W.H.O.
Unlike most viruses, smallpox, known as variola, is highly stable outside its host. It can long retain its power to infect, aiding its spread. Victims develop high fevers, deep rashes and oozing pustules. About a third die. In the 20th century alone, the virus is estimated to have taken more lives than all wars and other epidemics put together.
In 1959, the W.H.O. resolved to eradicate the killer in a blitz of global vaccinations and quarantines. Little was achieved until Washington and Moscow in 1966 proposed a stronger effort. That year alone, the disease killed two million people. By 1977, the W.H.O. recorded its last case, defeating the deadly scourge.
Today, the American W.H.O. exit may raise the risk of the smallpox virus escaping confinement and reinfecting the world, some health experts say. They see that threat as implicit in how past W.H.O. inspections of the C.D.C. smallpox labs made scores of recommendations for safety and security upgrades.
The proposals included better security systems, training, risk assessments, inspections of pressure suits, accident investigations and monitoring of staff competency.
David H. Evans, a virologist at the University of Alberta, has twice inspected the C.D.C. virus area and been a member of the W.H.O.'s smallpox scientific advisory panel.
While withdrawing from the W.H.O. may not increase the risk of a leak, he said, collaboration between the U.S. and the W.H.O. works quite effectively at improving research and lowering suspicions of illicit work.
'It keeps people talking to each other,' Dr. Evans said. 'It gets back to the idea of transparency. It gives you some idea of what's going on.'
Last year, a panel of the National Academy of Sciences described the cooperative smallpox research of the C.D.C. and the W.H.O. as 'urgently needed.' Looking beyond vaccines, the panel called for a new generation of antiviral drugs that would better fight smallpox in individuals already infected with the pathogen.
The W.H.O. research has had practical payoffs. Antiviral drugs developed by its smallpox program have been deployed to fight Mpox, formerly known as monkeypox, which is spreading quickly in parts of Africa, particularly in the Democratic Republic of Congo.
In 1996, W.H.O. members agreed on a plan to destroy the two remaining stocks of the smallpox virus. Now, increasingly, it aims to prepare for potential outbreaks rather than permanently extinguishing the virus.
But those heightened levels of defensive planning could be undone by the American withdrawal, health experts warn. They fear more countries may leave the W.H.O., spurring new outbreaks.
Michael T. Osterholm, the director of the Center for Infectious Disease Research and Policy at the University of Minnesota, noted that Argentina, echoing Mr. Trump, withdrew from the W.H.O. early this month, and that Hungary and Russia have also explored the idea.
'Global health safety is effective only if we have global representation,' Dr. Osterholm said. 'W.H.O. will do what it can. But at some point, we're going to have a real challenge.'
Dr. Frieden, the former C.D.C. director, agreed.
'Health is not a zero-sum game,' he said. 'When one country is healthy, it helps not only them, but their neighbors and the world.' He cited the purge of the smallpox virus from human populations as a remarkable case study in the benefits of global teamwork.
'There's no doubt that W.H.O. could be more effective,' Dr. Frieden added. 'But there's also no doubt that it's indispensable.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Texas Woman Dies From Brain-Eating Amoeba After Using RV Tap Water For Sinus Rinse
A Texas woman died from a rare and deadly brain infection after using unboiled tap water from an RV's water system for nasal irrigation while staying at a campground, according to the Centers for Disease Control and Prevention (CDC). The 71-year-old woman, who was healthy before the infection, used a nasal irrigation device with tap water from the RV's water system several times over four days. Within four days of her last use, she developed severe neurological symptoms, including fever, headache, and altered mental status, the CDC's Morbidity and Mortality Weekly Report stated. She developed seizures and died eight days after symptoms began. Laboratory testing confirmed Naegleria fowleri in her cerebrospinal fluid, indicating primary amebic meningoencephalitis (PAM), a disease with a fatality rate exceeding 97%. Naegleria fowleri, commonly known as the 'brain-eating amoeba,' is a free-living organism found in warm freshwater environments like lakes, rivers, and hot springs. Infections occur when contaminated water enters the nose, allowing the amoeba to travel to the brain. From 1962 to 2022, the U.S. reported 157 (primary amebic meningoencephalitis) PAM cases, with Texas accounting for 39. While most cases are linked to recreational water activities, nasal irrigation with contaminated water is a known risk. The CDC noted that the woman had no recent exposure to natural bodies of water, suggesting the RV's water system was the likely source of infection. The RV's water tank had been filled before the woman purchased it three months before her death, but the filling location is unknown. No samples from the campsite or RV water system tested positive for the amoeba, leaving the exact source of contamination unclear. The CDC emphasized that only distilled, sterile, or previously boiled water should be used for nasal rinsing, as tap water, even if safe for drinking, may contain organisms harmful when introduced into the nasal passages. To prevent PAM, the CDC recommends holding your nose or wearing a nose clip when diving into freshwater, keeping your head above water in hot springs, avoiding digging in shallow water, and using boiled or distilled water for nasal irrigation. The specific Texas campground where the infection occurred was not disclosed. This case underscores the critical need for public awareness about safe water use for nasal irrigation to prevent such rare but devastating infections.


New York Post
20 minutes ago
- New York Post
Menopause drug might prevent breast cancer and treat hot flashes, research finds
A drug intended to treat menopause symptoms could double as breast cancer prevention. New research from Northwestern University in Illinois found that Duavee, a Pfizer-made drug, 'significantly reduced' breast tissue cell growth, which is a major indicator of cancer progression. Advertisement A phase 2 clinical trial included 141 post-menopausal women who had been diagnosed with ductal carcinoma in situ (DCIS), also known as stage 0 breast cancer, according to a press release from Northwestern. This non-invasive breast cancer affects more than 60,000 American women each year, often leading to an outcome of invasive breast cancer. The women were separated into two groups — one received Duavee and the other took a placebo for a month before undergoing breast surgery. Duavee is a conjugated estrogen/bazedoxifene (CE/BZA) drug, which combines estrogen with another medication that minimizes the potential harmful side effects of the hormone. Advertisement 'The key takeaway from the study is that CE/BZA slows the growth (proliferation) of cells in milk ducts of DCIS that expressed the estrogen receptor significantly more than placebo,' Dr. Swati Kulkarni, lead investigator and professor of breast surgery at Northwestern University Feinberg School of Medicine, told Fox News Digital. 5 New research from Northwestern University found that the drug Duavee 'significantly reduced' breast tissue cell growth, a major indicator of cancer progression. Marko Geber – Another major finding is that the quality of life did not differ significantly between the two groups, but patients who took the CE/BZA reported fewer hot flashes during the study, she noted. 'This would be expected, as the drug is FDA-approved to treat hot flashes.' Advertisement Kulkarni presented the study last week at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. 5 The women in the study were separated into two groups — one received Duavee and the other took a placebo for a month before undergoing breast surgery. Gorodenkoff – 5 Those who took the drug reported fewer hot flashes during the study. fizkes – The findings are preliminary and have not yet been published in a medical journal. Advertisement 'What excites me most is that a medication designed to help women feel better during menopause may also reduce their risk of invasive breast cancer,' said the doctor, who is also a Northwestern Medicine breast surgeon. Women who face a higher risk of breast cancer — including those who have experienced 'high-risk lesions' — and who also have menopausal symptoms are most likely to benefit from the drug, according to Kulkarni. 'These women are typically advised against standard hormone therapies, leaving them with few menopausal treatment options,' the release stated. Study limitations The researchers said they are 'encouraged' by these early results, but more research is required before the medication can be considered for approval as a breast cancer prevention mechanism. 'Our findings suggest that CE/BZA may prevent breast cancer, but larger studies with several years of follow-up are needed before we would know this for sure,' Kulkarni told Fox News Digital. Dr. Sheheryar Kabraji, chief of breast medicine at the Roswell Park Comprehensive Cancer Center in Buffalo, New York, was not involved in the study but commented on the findings. 5 'What excites me most is that a medication designed to help women feel better during menopause may also reduce their risk of invasive breast cancer,' Dr. Swati Kulkarni said. sarayutsridee – Advertisement 'While intriguing, this study is highly preliminary, and more research will be needed before we can conclude that conjugated estrogen/bazedoxifene (CD/BZA), a form of the hormone estrogen commonly prescribed to address symptoms of menopause, prevents invasive breast cancer or is effective at reducing cancer risk,' he told Fox News Digital. Kabraji also noted that the study focused on reducing levels of one specific protein, 'which does not always predict reduced recurrence of breast cancer.' 'This study did not directly show that CE/BZA treatment reduces the risk of DCIS recurrence or development of invasive cancer,' he noted. 5 According to Kulkarni,'larger studies with several years of follow-up are needed' to confirm that the drug prevents breast cancer. Science RF – Advertisement 'Importantly, however, patients who received this therapy experienced no worsening of quality of life, and saw improvement in vasomotor symptoms, such as hot flashes. If found to be effective in preventing breast cancer, CE/BZA is likely to have fewer side effects than current medications used for breast cancer prevention.' Lead researcher Kulkarni emphasized that this medication is not for the treatment of invasive breast cancer or DCIS. 'Right now, we can say that women who are concerned about their risk of developing breast cancer can consider this medication to treat their menopausal symptoms,' she added.


Washington Post
2 hours ago
- Washington Post
NASA, Pentagon push for SpaceX alternatives amid Trump's feud with Musk
Federal officials at NASA and the Pentagon moved swiftly this week to urge competitors to Elon Musk's SpaceX to more quickly develop alternative rockets and spacecraft after President Donald Trump threatened to cancel Space X's contracts and Musk's defiant response. Government officials were especially stunned after Musk responded to Trump with a salvo of his own: SpaceX would stop flying its Dragon spacecraft, a move that would leave the space agency with no way to transport its astronauts to the International Space Station.